Skip to main content

Me NaPhos MB Hyo 1

Generic: Urinary Antiseptic Antispasmodic

Verified·Apr 23, 2026
Manufacturer
Method
NDC
58657-454
RxCUI
1050325
Route
ORAL
ICD-10 indication
N30.90

Affordability Check

How much will you actually pay for Me NaPhos MB Hyo 1?

In 30 seconds, see every legitimate way to afford Me NaPhos MB Hyo 1 — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.

Check my options →

About Me NaPhos MB Hyo 1

What is this medication?

Me NaPhos MB Hyo 1 is a combination prescription medication primarily used to relieve symptoms of lower urinary tract irritation. It is frequently prescribed to alleviate discomfort, burning sensations, and the frequent or urgent need to urinate that can occur with conditions such as cystitis or after certain medical procedures involving the bladder. The medication is designed to provide symptomatic relief by addressing both the physical spasms of the urinary tract and the chemical environment of the urine.

The drug contains four active ingredients that work together to manage urinary distress. Methenamine and methylene blue act as mild antiseptics to help inhibit the growth of bacteria in the urinary tract, while sodium phosphate monobasic is used to acidify the urine, which helps the methenamine work more effectively. Additionally, hyoscyamine sulfate serves as an antispasmodic that relaxes the smooth muscles of the bladder, helping to reduce painful cramping and the constant urge to go.

Copay & patient assistance

Detailed copay and financial assistance information is not publicly available for this medication at this time. Please consult your pharmacist or the manufacturer's official patient support program for more details.

External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.

Compare pricing elsewhere

RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.

We deep-link because transparency helps patients. None of these partners pay RxCopays.

Prescribing information

From the FDA-approved label for Me NaPhos MB Hyo 1. Official source: DailyMed (NLM) · Label effective Oct 21, 2025

Indications and usage
INDICATION AND USAGE ME/NaPhos/MB/Hyo 1 Tablets is indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as hypermotility which accompany lower urinary tract infections and as antispasmodic. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures.
Dosage and administration
DOSAGE AND ADMINISTRATION Adults One tablet orally 4 times per day followed by liberal fluid intake. Older Children Dosage must be individualized by physician. Not recommended for use in children up to 6 years of age.
Warnings
WARNINGS Do not exceed recommended dosage. If rapid pulse, dizziness, or blurring of vision occurs discontinue use immediately.
Drug interactions
Drug Interactions because of this product's effect on gastrointestinal motility and gastric emptying, it may decrease the absorption of other oral medications during concurrent use such as: urinary alkalizers; thiazide diuretics (may cause the urine to become alkaline reducing the effectiveness of methenamine by inhibiting its conversion to formaldehyde); antimuscarinics (concurrent use may intensify antimuscarinic effects of hyoscyamine because of secondary antimuscarinic activities of these medications); antacids/antidiarrheals (may reduce absorption of hyoscyamine, concurrent use with antacids may cause urine to become alkaline reducing effectiveness of methenamine by inhibiting its conversion to formaldehyde) doses of these medications should be spaced 1 hour apart from doses of hyoscyamine; antimyasthenics (concurrent use with hyoscyamine may further reduce intestinal motility); ketoconazole (patients should be advised to take this combination at least 2 hours after ketoconazole); monoamine oxidase (MAO) Inhibitors (concurrent use may intensify antimuscarinic side effects, opioid (narcotic) analgesics may result in increased risk of severe constipation); sulfonamides (these drugs may precipitate with formaldehyde in the urine, increasing the danger of crystalluria). Patients should be advised that the urine may become blue to blue green and the feces may be discolored as a result of the excretion of methylene blue.
Adverse reactions
ADVERSE REACTIONS Cardiovascula r – rapid pulse, flushing Central Nervous System – blurred vision, dizziness Respiratory – shortness of breath or troubled breathing Genitourinary – difficulty micturition, acute urinary retention Gastrointestinal – dry mouth, nausea/vomiting

Label text is reproduced as-is from the FDA-approved label. We do not paraphrase, summarize, or omit. Content above is for informational purposes only and is not medical advice. Always consult your prescribing clinician or pharmacist before making decisions about your medication.

Conditions we've indexed resources for

Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.

Prior authorization & coverage

PayerPAStep therapyCopay tier

Medicare Part D

Related drugs

How this page is sourced

  • Drug identity verified against openFDA NDC Directory.
  • Label text (when shown) originates from NLM DailyMed.
  • Copay and assistance URLs verified periodically; if you hit a broken link, tell us.